<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-439
Date of Submission: 2025-04-25

This report was submitted by a Nurse from Reed-Koch Medical Center concerning patient ANON-PX-4794. The subject is a 52-year-old male with a significant medical history including osteoarthritis, chronic kidney disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intravenous route at a dosage of 115mg, initiated on 2025-02-27 for Hypercholesterolemia with the course ongoing.

On approximately 2025-04-08, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Nausea. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Mouth available feel public member only. Ago shoulder hospital single. Tree prevent enter practice development.</data>
report_id: ADR-2025-439
report_date: '2025-04-25'
patient_details:
  patient_id: ANON-PX-4794
  gender: Male
  relevant_history:
  - osteoarthritis
  - chronic kidney disease
  - seasonal allergies
  age_at_reaction: 52
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 115mg
  route_of_administration: Intravenous
  start_date: '2025-02-27'
  indication_for_use: Hypercholesterolemia
adverse_reactions:
- symptom_name: Pruritus
  onset_date: '2025-04-08'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
- symptom_name: Nausea
  onset_date: '2025-04-08'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 5
reporting_facility: Reed-Koch Medical Center
reporter_type: Nurse
notes: Mouth available feel public member only. Ago shoulder hospital single. Tree
  prevent enter practice development.
